Gilead Sciences, Inc. $GILD Shares Bought by National Pension Service

National Pension Service raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,370,643 shares of the biopharmaceutical company’s stock after purchasing an additional 109,230 shares during the period. National Pension Service’s holdings in Gilead Sciences were worth $374,141,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. GoalVest Advisory LLC raised its stake in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth about $27,000. Putney Financial Group LLC raised its position in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute acquired a new position in Gilead Sciences in the second quarter valued at approximately $30,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $141.95 on Friday. The firm has a market cap of $176.11 billion, a P/E ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $142.20. The business’s 50-day moving average price is $125.36 and its 200 day moving average price is $119.59. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the firm earned $2.02 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on GILD shares. Needham & Company LLC raised their price objective on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. TD Cowen increased their target price on shares of Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday. HSBC boosted their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a research report on Wednesday, December 10th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Finally, Morgan Stanley cut their target price on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $136.36.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the transaction, the director directly owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. The trade was a 67.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total transaction of $1,398,900.00. Following the completion of the sale, the chief executive officer owned 556,698 shares of the company’s stock, valued at $77,876,483.22. This trade represents a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 257,397 shares of company stock valued at $33,385,512. Corporate insiders own 0.27% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.